Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.61 |
| ▸ | KAT8 | Q9H7Z6 | 5/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | EP300 | Q09472 | 2/20 | 0.54 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.53 |
| ▸ | BID | P55957 | 3/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.53 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.53 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.53 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10880566 | 0.98 | PPARA (0.64) | PPARAKAT8PTGS2CYP3A4EP300 | |
| SCHEMBL11109182 | 0.85 | PTGS2 (0.55) | PPARAKAT8PTGS2CYP3A4NPC1 | |
| SCHEMBL11103507 | 0.84 | PTGS2 (0.56) | PPARAKAT8PTGS2CYP3A4NPC1 | |
| Bicarbonate SCHEMBL4374124 | 0.81 | PPARA (0.61) | PPARAKAT8PTGS2CYP3A4NPC1 | |
| Bicarbonate SCHEMBL4372923 | 0.81 | PPARA (0.61) | PPARAKAT8PTGS2CYP3A4NPC1 | |
| SCHEMBL28368563 | 0.81 | PPARA (0.69) | PPARAKAT8PTGS2CYP3A4NPC1 | |
| SCHEMBL6503019 | 0.81 | PTGS2 (0.50) | PPARAKAT8PTGS2CYP3A4NPC1 | |
| SCHEMBL8733021 | 0.80 | RARB (0.54) | PPARAKAT8PTGS2CYP3A4EP300 | |
| SCHEMBL20556197 | 0.80 | RARB (0.54) | PPARAKAT8PTGS2CYP3A4EP300 | |
| SCHEMBL9243477 | 0.80 | RARB (0.54) | PPARAKAT8PTGS2CYP3A4GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4132787-A | ARTERIOSCLEROSIS | SCIENCE UNION ET CIE (FR) | 1979-01-02 | — | — | US | claimed |
| US-12612358-B2 | Resorcinol-based compounds and uses thereof | SUTTER BAY HOSPITALS (US) | 2026-04-28 | — | — | US | disclosed |
| US-20240059646-A1 | RESORCINOL-BASED COMPOUNDS AND USES THEREOF | ORGANIX INC. | 2024-02-22 | — | — | US | disclosed |
| WO-2022133058-A1 | RESORCINOL-BASED COMPOUNDS AND USES THEREOF | SUTTER BAY HOSPITALS (US) | 2022-06-23 | — | — | WO | disclosed |
| US-20090042974-A1 | Compositions And Methods Relating To Extensible Transgenic Vector Assembler, Pestilence Ridder, Plus Cannabinoid Producer | PARKER ANSON DAVID | 2009-02-12 | — | — | US | disclosed |
| US-6972340-B2 | Selective protein tyrosine phosphatatase inhibitors | ABBOTT LABORATORIES (US) | 2005-12-06 | — | — | US | disclosed |
| WO-2003072537-A2 | SELECTIVE PROTEIN TYROSINE PHOSPHATATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003020688-A1 | SELECTIVE PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2003-03-13 | — | — | WO | disclosed |
| US-20020169157-A1 | Selective protein tyrosine phosphatatase inhibitors | ABBOTT LABORATORIES | 2002-11-14 | — | — | US | disclosed |
| US-20020072516-A1 | Selective protein tyrosine phosphatatase inhibitors | ABBVIE INC. | 2002-06-13 | — | — | US | disclosed |
| US-4132787-A | ARTERIOSCLEROSIS | SCIENCE UNION ET CIE (FR) | 1979-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612358-B2 | Resorcinol-based compounds and uses thereof | CARM1, MALT1, RCOR1 | PPARA 2408/4885KAT8 1771/4885PTGS2 3672/4885 |
| US-20240059646-A1 | RESORCINOL-BASED COMPOUNDS AND USES THEREOF | VHL, NQO1, HRAS | PPARA 896/4885KAT8 3537/4885PTGS2 2792/4885 |
| US-20020169157-A1 | Selective protein tyrosine phosphatatase inhibitors | PPM1B, PPM1A, PPM1D | PPARA 4103/4885KAT8 3941/4885PTGS2 4451/4885 |
| US-20020072516-A1 | Selective protein tyrosine phosphatatase inhibitors | PPM1B, PPM1A, PPM1D | PPARA 4103/4885KAT8 3941/4885PTGS2 4451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.